Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

Good point...Thanks for pointing that out LR !

My interpetation of both BDD PR's for IPIX's Brilacidin and Cingulate's dexmethylphenidate hydrochloride is BDD is most likely currently working on a similar Proof of Concept for drug delivery study demonstrating Brilacidin levels in the small intestine,colon and distal colon.

As you know drug delivery in those areas would target Crohn's disease which frequently affects the small intestine, Ulcerative Colitis and Irritable Bowel Syndrome which affects the entire colon and Ulcerative Proctitis which affects the distal colon.

Delivering Brilacilin, a Human defense protein mimetic, to the entire colon would help prove the theory that inflammatory bowel disease is at least partially related to diminished Paneth cell secretion of human definsin proteins to the gastrointestinal tract.

IMO this determination would help IPIX and their potential term sheet partner plan the upcoming FDA studies and could lead to the FDA approving accelerated development.

GLTA, Farrell